Suh 2006

Methods	RCT: enrolled: 538 evaluated: 515
Participants	Inclusion: 1. RPA class I or II 2. no prior brain metastases treatment 3. age ≥ 18 years 4. adequate hematologic, hepatic, renal function 5. no other concurrent active malignancy 6. no planned therapy for brain metastases one month post follow‐up visit 7. pulse oximetry ≥ 90% Exclusion: 1. small cell lung cancer, germ cell or lymphoma 2. pregnant or breast‐feeding 3. prior exposure to efaproxiral 4. chemotherapy within seven days or investigational agents within 28 days of whole brain radiotherapy
Interventions	3000 cGy/10 fr versus 3000 cGy/10 fr plus efaproxiral
Outcomes	1. Survival 2. Radiographic brain response 3. Radiologic and clinical brain progression 4. Cause of death 5. Quality of life
Notes	QS = 3